As the COVID-19 pandemic moves into an endemic phase, the major impacts on drug research, collaboration, and use of new technologies due to the spread of the virus warrant recognition.
Phil Mounteney
Advertisement
Phil Mounteney is the Regional Vice President of Science & Technology, North America at Dotmatics, the global leader in R&D scientific software that connects science, data, and decision-making. Phil has worked in a variety of leadership roles at Domatics since 2009.
Articles by Phil Mounteney
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity
2
From Type 1 to Type 2 and Beyond: Navigating the Landscape of Diabetes
3
COVID-19 Reinfection Heightens Risk of Postacute Sequelae of SARS-CoV-2 in Pediatrics
4
Doxecitine–Doxribtimine Becomes First Approved Treatment for Rare Genetic Disorder
5
